TABLE 2.
Off-label request characteristics and univariate logistic regression analysis for treatment initiation (n = 708).
| Characteristic | Total n (%) | Treatment initiated n = 583 n (%) | Treatment not initiated n = 125 n (%) | Odds ratio | 95% CI for odds ratio lower upper | p-value |
| Drug type | ||||||
| Chemotherapy | 144 (20) | 122 (21) | 22 (18) | 1.239 | 0.750–2.046 | 0.402 |
| Targeted therapy | 272 (39) | 208 (36) | 64 (51) | 0.529 | 0.358–0.780 | 0.001 |
| Immunotherapy | 292 (41) | 253 (43) | 39 (31) | 1.691 | 1.119–2.553 | 0.013 |
| Metastatic disease | 491 (69) | 417 (72) | 74 (59) | 1.731 | 1.161–2.581 | 0.007 |
| Orphan disease | 276 (39) | 227 (39) | 49 (39) | 0.989 | 0.666–1.469 | 0.956 |
| Marker or targetable mutation | 179 (25) | 157 (27) | 22 (18) | 1.725 | 1.051–2.832 | 0.031 |
| Treatment line | ||||||
| ≥2 | 377 (53) | 318 (55) | 59 (47) | 1.342 | 0.911–1.977 | 0.136 |
| ≥3 | 109 (15) | 90 (15) | 19 (15) | 1.018 | 0.595–1.743 | 0.947 |
| Supporting evidence | ||||||
| Sufficient | 338 (48) | 226 (45) | 72 (58) | 1.619 | 1.096–2.392 | 0.016 |
| Limited | 322 (45) | 278 (48) | 44 (35) | 0.596 | 0.399–0.899 | 0.012 |
| Inadequate | 48 (7) | 39 (7) | 9 (7) | 1.082 | 0.510–2.296 | 0.837 |
| Financing | ||||||
| Expanded access | 210 (30) | 187 (32) | 23 (18) | 2.094 | 1.290–3.400 | 0.003 |
| Charity | 17 (2) | 16 (3) | 1 (1) | 3.499 | 0.440–26.632 | 0.226 |
| Out-of-pocket | 84 (12) | 71 (12) | 13 (10) | 1.195 | 0.639–2.233 | 0.557 |
| Private insurance | 178 (25) | 152 (26) | 21 (21) | 1.343 | 0.839–2.148 | 0.219 |
| No planned source | 219 (31) | 157 (27) | 62 (50) | 0.374 | 0.252–0.556 | <0.0005 |
| Cost per month (ILS), Mean | 54,703 | 56,274 | 47,313 | 1 | 1–1 | 0.125 |
ILS, New Israeli Shekels.